Eli Lilly Partners With Amazon On Prescription Delivery Program
Eli Lilly has partnered with Amazon Pharmacy to deliver medicine as part of its service, LillyDirect Pharmacy Solutions.
Read MoreEli Lilly has partnered with Amazon Pharmacy to deliver medicine as part of its service, LillyDirect Pharmacy Solutions.
Read MoreIndiana University Indianapolis and Eli Lilly and Company are launching a new co-op partnership to enhance talent pipelines and expand workforce development opportunities for people in central Indiana.
Read MoreIndianapolis-based drugmaker Eli Lilly reportedly agreed May 26 to pay $13.5 million to settle a class-action lawsuit alleging the company has for years overpriced insulin products.
Read MoreAl Campbell was born in Richmond and from K-12th grade, lived in eight different towns.
Read MoreSYRACUSE — Merrell Harkless of Harkless Boat Company (now known as Wawasee Boat Company) built a line of boats over 100 years ago. There were reportedly only 60 of built. Today only one of those remain and it has been in dry-dock for over 20 years. The boat … Read More
SYRACUSE — Hundreds converged on the Syracuse-Wawasee Historical Museum Saturday, May 18, not only to view J.P. Dolan’s Indian Relic collection, but other area historical items displayed, during an open house. Many were also on hand for a brief presentation from J.P. Dolan, Eli Lilly, Chief Papakeechie … Read More
SYRACUSE — The Syracuse-Wawasee Historical Museum, located in the Syracuse Community Center, North Long Drive, Syracuse, is hosting “Eli Lilly and the Dawn of Indiana Archaeology,” at 10:30 a.m. and 1 p.m. Saturday, Sept. 23. The event will be held in Celebration Hall. The event is being held … Read More
INDIANAPOLIS — Eli Lilly and other drugmakers saw their stocks jump after the elections results, and the market for legal marijuana could surpass $20 billion.
Read MoreSYRACUSE — Syracuse-Wawasee Trail Committee met Monday evening, April 18, and Megan McClellan, executive director, gave the committee an update on several trail projects.
Read MoreBy ANDREA NEAL From the time he was a youngster, Eli Lilly was fascinated by pharmaceuticals. At 16, he served as an apprentice at the Good Samaritan Drugstore in Lafayette. During the day, he stocked shelves, washed bottles and ran errands. At night, he pored over the United … Read More
By Andy Ober Assistant Managing Editor, Inside Indiana Business INDIANAPOLIS — Indiana’s life sciences initiative has been awarded a two-year, $2.9 million grant from Lilly Endowment Inc. BioCrossroads says the funding will support its ongoing charitable, educational and scientific efforts. BioCrossroads Chief Executive Officer, David Johnson, says the … Read More
By GERRY DICK Inside Indiana Business INDIANAPOLIS — Indianapolis-based Eli Lilly and Co. Chief Executive Officer, John Lechleiter, said the drug maker is back in growth mode after a painful period of “building a bridge while we crossed it.” In a speech Friday, Sept. 11, to the Economic Club of … Read More
Turkey Creek Township Trustee Barb Griffith reported Monday on an unwitting snafu by the contracted groundskeeper of Bethel Cemetery. In remediating the condition of the cemetery’s vegetation, the groundskeeper removed two cedar trees in the northeast corner of the cemetery. Griffith heard from three citizens who objected to … Read More
Eli Lilly and Company announced yesterday that the European Commission granted marketing authorization for Trulicity (dulaglutide) solution for injection. Trulicity, a GLP-1 receptor agonist, is a once-weekly, injectable solution designed to improve glycaemic control in adults with type 2 diabetes. The medicine comes in a ready-to-use pen with … Read More
Eli Lilly and Company (NYSE: LLY) today announced that SQUIRE, a recently completed Phase III study, met its primary endpoint, finding that patients with stage IV metastatic squamous non-small cell lung cancer experienced increased overall survival when administered necitumumab in combination with gemcitabine and cisplatin as a first-line … Read More
Eli Lilly and Company (NYSE: LLY) announced today Phase III clinical trial results from enzastaurin’s PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). The study failed to show a statistically significant increase compared to … Read More